Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Parkinson Disease 4, Autosomal Dominant Lewy Body 25Lung Neoplasms 25Squamous Cell Carcinoma of Head and Neck 20Melanoma 19Neoplasm Metastasis 18Neoplasms 16Endometrial Neoplasms 14Colorectal Neoplasms 14Breast Neoplasms 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 11Head and Neck Neoplasms 9Carcinoma, Renal Cell 8Pancreatic Neoplasms 7Carcinoma, Transitional Cell 7Urinary Bladder Neoplasms 6Recurrence 5Lymphoma 5Hodgkin Disease 5Esophageal Neoplasms 4Carcinoma 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Prostatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

pembrolizumab 1atezolizumab 1PT-100 dipeptide 1PM 01183 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × pembrolizumab × 30 days × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡